|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenue | |||||
| Cost of revenue | |||||
| Gross profit (loss) | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (income) expenses, net: | |||||
| Change in fair value of preferred stock warrant and contingent shares liability | |||||
| Change in fair value of derivative liability | |||||
| Change in fair value of contingent shares liability | |||||
| Gain on sale of intangible assets | |||||
| Interest expense | |||||
| Interest income | |||||
| Other expense, net | |||||
| Total other (income) expenses, net | |||||
| Loss before income tax expense | |||||
| Income tax expense | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Unrealized (loss) gain resulting from change in fair value of marketable securities | |||||
| Total comprehensive loss | |||||
| Cumulative dividends on convertible preferred stock | |||||
| Net loss attributable to common stockholders | |||||
| Loss per common share | |||||
| Basic | |||||
| Total basic | |||||
| Diluted | |||||
| Total diluted | |||||
| Weighted-average common shares outstanding | |||||
| Basic | |||||
| Total basic | |||||
| Diluted | |||||
| Total diluted | |||||
Loading...